Clinical Study of Probucol

The effect and safety of a new cholesterol- lowering drug, probucol, was investigated in 49 hypercholesterolemia patients in Kyushu multicentral cooperative study (10 hospitals). The patients were allocated to either 750mg or 1000mg per day for 16 weeks. Both doses of probucol lowered serum cholesterol, LDL-cholesterol and HDL-cholesterol and phospholipid significantly without influencing on serum tryglyceride levels. No relationship among two doses of probucol and the degree of cholesterol lowering have been found in this study. And at all doses employed, the drug was well tolerated and no changes attributable to therapy were observed in the laboratory parameters evaluated.